RxDoctor Payments Data

Melanie Lozano

Physician Assistant · Layton, UTNPI 1760886634

Payments from drug & device makers

$5,003in general payments, 2019–2025

Across 300 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Astellas Pharma US Inc$384
  • Amarin Pharma, Inc.$269
  • Otsuka America Pharmaceutical, Inc.$249
  • Abbott$213
  • Lilly USA, LLC$202
  • plus $2K from 41 others

What the payments were for

  • Food & beverage$4,83597%
  • Education$1683%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,003 in reported general payments places this provider in the 90th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$20,233
Medicare patients
100
Services billed
312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol40$34,082
OzempicSemaglutide27$29,743
MounjaroTirzepatide22$21,671
Omeprazole29$567
Levothyroxine Sodium66$474
Fluticasone Propionate16$418
Ibuprofen12$299
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav22$286
Atorvastatin Calcium42$251
Bupropion XlBupropion Hcl12$230
Albuterol Sulfate HfaAlbuterol Sulfate12$219
Fluoxetine Hcl13$211
Gabapentin11$159
Pioglitazone Hcl18$153
Lisinopril27$145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$83$34,08240 claims
Novo NordiskOzempic$114$29,74327 claims
Lilly USA, LLCMounjaro$202$21,67122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Layton

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →